microRNAs linked to nusinersen response in SMA

External site

By following this link, you are leaving Medically and entering a website that is not owned or controlled by Roche. Roche does not take any responsibility for access to or use of this website, nor for any content therein.

Oct 12 / Springer Healthcare

microRNAs linked to nusinersen response in SMA

Neuroscience Spinal Muscular Atrophy WMS-2022

Description

Sharon Aharoni talks us through the results of a study showing that lower baseline levels of two muscle microRNAs measured in the cerebrospinal fluid are associated with better clinical response to nusinersen treatment in patients with type 2 or 3 spinal muscular atrophy.

Follow us here

This website is intended for healthcare professionals outside the United Kingdom (UK) and Australia. Registration status and prescribing information of medicinal products may differ between countries. Please refer to local product information for any medicinal products mentioned on this website.